||5R01CA207078-06 Interpret this number
||University Of Tx Md Anderson Can Ctr
||Optimizing Effectiveness of Smoking Cessation Intervention During Ldct Screening for Lung Cancer
The low-dose computed tomography (LDCT) lung cancer screening environment may provide a unique
opportunity to deliver evidence-based smoking cessation treatments at a time where smokers' interest in health
concerns may make them particularly receptive to a quitting message. While there are well established
methods for smoking cessation in the general community, the optimal configuration of a smoking cessation
intervention in a real-world lung cancer screening setting has not been established. It seems clear that such
interventions should go beyond the provision of passively providing smoking cessation advice, but the
intervention modality, level of intensity and degree of integration with the screening setting is unknown.
Despite enthusiasm for integrating smoking cessation programs within health care settings there have been few
attempts to actually develop such programs. The proposed research will be among the first to focus on
identifying the optimal configuration for integrating a program into the LDCT for lung cancer screening. This
study will also ascertain the cost-effectiveness and value of implementation of increasingly more integrative
and intensive strategies. This will enable decision makers and other stakeholders to assemble a cessation
program that provides maximum effectiveness while considering resource allocation efficiency within their
LDCT screening environment. The present proposal focuses on the relative effectiveness and cost of three
major components of a smoking cessation intervention: a publically available cessation quitline; level of
involvement of LDCT medical providers; and integration of smoking cessation specialists within the LDCT
setting. Smokers (N=630) will be randomly assigned to three groups: Quitline (QL); Quitline-Rx (QL-Rx); and
Integrated Care (IC). The QL intervention is intended to model the real-world situation in which smokers
who present for lung cancer screening are provided standard care (brief advice for smoking cessation) and
referred to the quitline for smoking cessation counseling and nicotine replacement therapy. The Quitline-Rx
group is intended to model an environment in which the LDCT medical provider assumes an active role in
selecting and managing available pharmacotherapy for smoking cessation, and the quitline serves as the
provider for smoking cessation counseling. The Integrated Care intervention (IC) presents the highest level of
care and is models an environment in which smoking cessation counseling and medication management are
provide by smoking cessation specialists within that setting. The major contribution of this research is
expected to be a change in clinical practice and advancing a model for providing integrated smoking cessation
treatment as a “gold” standard for LDCT lung cancer screening settings across the country. Ultimately the
availability of smoking cessation services will enhance the impact of lung cancer screening on the public health
by reducing smoking related illness.
Engaging smokers in research: Utility of Facebook in facilitating recruitment to a smoking cessation study.
, Jerome R.N.
, Dunagan J.
, Kennedy N.
, Edwards T.
, Minnix J.A.
, Witmer L.
, Ferguson J.
, Cinciripini P.
, Wilkins C.
, et al.
Contemporary clinical trials, 2021 08; 107, p. 106461.
Predictors of Enrollment of Older Smokers in Six Smoking Cessation Trials in the Lung Cancer Screening Setting: The Smoking Cessation at Lung Examination (SCALE) Collaboration.
, Williams R.M.
, Luta G.
, Kim E.
, Toll B.A.
, Rojewski A.
, Neil J.
, Cinciripini P.M.
, Cordon M.
, Foley K.
, et al.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2021-06-02; , .
Impact of the COVID-19 pandemic on telehealth research in cancer prevention and care: A call to sustain telehealth advances.
, Chiles C.
, Cinciripini P.M.
, Foley K.L.
, Fucito L.M.
, Haas J.S.
, Joseph A.M.
, Ostroff J.S.
, Rigotti N.A.
, Shelley D.R.
, et al.
Cancer, 2021-02-01; 127(3), p. 334-338.